Natural Alternatives International Inc當前公司基本面數據相對穩定,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在藥品行業排名115/159位。機構持股佔比非常高,中期看,股價處於上升通道。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。
Natural Alternatives International Inc評分
相關信息
行業排名
115 / 159
全市場排名
359 / 4521
所屬行業
藥品
壓力支撐
由於公司未披露,未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
Natural Alternatives International Inc亮點
亮點風險
Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. Its primary business activity is to provide private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers both within and outside the United States. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer ecommerce channels, and retail stores. It manufactures products in a variety of forms, including capsules, tablets, chewable wafers, and powders to accommodate a variety of its customer’s preferences. It also seeks to commercialize its patent and trademarks through the direct distribution and sale of CarnoSyn, SR CarnoSyn, TriBsyn, new contract manufacturing opportunities, and various license, royalty, and similar arrangements.
Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. Its primary business activity is to provide private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers both within and outside the United States. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer ecommerce channels, and retail stores. It manufactures products in a variety of forms, including capsules, tablets, chewable wafers, and powders to accommodate a variety of its customer’s preferences. It also seeks to commercialize its patent and trademarks through the direct distribution and sale of CarnoSyn, SR CarnoSyn, TriBsyn, new contract manufacturing opportunities, and various license, royalty, and similar arrangements.